Search Results
Your search for Caroline Helwick matches 2444 pages
Showing 2051 - 2100Cetuximab Confers Survival Benefit in All-RAS Wild-Type Colorectal Tumors
The FIRE-3 study compared the two epidermal growth factor receptor (EGFR) antibodies, on top of chemotherapy, in the first-line treatment of metastatic colorectal cancer. A preplanned analysis of KRAS wild-type patients without RAS mutations, ie, “all-RAS wild-type,” showed overall survival to be...
Time to Think Beyond KRAS in Metastatic Colorectal Cancer
Eric Van Cutsem, MD, PhD, Professor of Internal Medicine at the University of Leuven in Belgium, told attendees at the 2013 European Cancer Congress that in the management of metastatic colorectal cancer, it is time to expand KRAS testing to include more rare mutations. Until recently, KRAS status...
Expert Point of View: Eric Van Cutsem, MD, PhD
Eric Van Cutsem, MD, PhD, Professor of Internal Medicine at the University of Leuven in Belgium, the formal discussant of the late-breaking abstract, noted there is strong rationale for studying TP53 status in relation to rectal cancer outcomes, but he felt the findings of EXPERT-C could not yet be ...
TP53 Status May Predict Benefit From Cetuximab in Locally Advanced Rectal Cancer
In a retrospective analysis of the randomized phase II EXPERT-C trial, TP53 emerged as a strong, independent predictive biomarker for the benefit of cetuximab (Eribitux) in MRI-defined high-risk, locally advanced rectal cancer, according to Francesco Sclafani, MD, of The Royal Marsden NHS...
Expert Point of View: David Sebag-Montefiore, MD
David Sebag-Montefiore, MD, Professor of Clinical Oncology at the University of Leeds and St. James’s Institute of Oncology in the United Kingdom, was the invited discussant of the PROCTOR/SCRIPT study. He noted that in this 470-patient study, the disease-free and overall survival hazard ratios...
In Operable Rectal Cancer, No Support Found for Adjuvant Chemotherapy
For patients with operable rectal cancer, there is no clear role for adjuvant chemotherapy, according to an analysis of the PROCTOR and SCRIPT trials from the Dutch Colorectal Cancer Group. The findings were presented by Anne J. Breugom, MD, of Leiden University Medical Center in the Netherlands,...
Metastatic Melanoma: Encouraging Data Keep Coming
Excitement continues to build in the metastatic melanoma arena, as novel agents keep upping the ante for efficacy. The following news from the 2013 European Cancer Congress has added to the buzz. New MEK Inhibitor In the phase IB BRIM7 study, cobimetinib, a novel MEK inhibitor, when combined with...
Brentuximab and PET-Adapted Salvage May Eliminate Toxic Chemotherapy for Refractory Hodgkin Lymphoma
Relapsed and refractory transplant-eligible Hodgkin lymphoma patients who achieve complete responses after treatment with brentuximab vedotin (Adcetris) can often avoid more toxic salvage chemotherapy, according to investigators from Memorial Sloan-Kettering Cancer Center, New York....
SIDEBAR: Addition of Novel Agents May Improve Outcomes With ABVD
In North America, the standard front-line treatment for advanced Hodgkin lymphoma is ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), but this regimen is not effective in all patient subsets. To improve upon the regimen’s efficacy, researchers are evaluating new combinations, said Stephen...
Brentuximab Vedotin Improves Response Rates to ABVD in Hodgkin Lymphoma
For the front-line treatment of advanced Hodgkin lymphoma, ABVD is a standard treatment, but not all patients have good outcomes with this regimen. The addition of brentuximab vedotin (Adcetris), or its substitution for bleomycin, produces high complete response rates but with a moderate increase...
Expert Point of View: Daniel F. Hayes, MD, FASCO
Daniel F. Hayes, MD, FASCO, the Stuart B. Padnos Professor of Breast Cancer Research at the University of Michigan, Ann Arbor, wrote an accompanying editorial on the value of these newly developed omics-related criteria.1 Dr. Hayes pointed out that since the cloning of the human genome, there has...
NCI-Led Scientists Develop Criteria for 'Omics' Tests Used in Clinical Investigations
High-throughput “omics” technologies that generate molecular profiles on tumor specimens are increasingly being incorporated into clinical trials, but some of these assays have not been well validated, leading many in the research community to question their fitness for use in patient-care...
Continuous, Combined Hormone Replacement Therapy Protects Against Endometrial Cancer
According to an analysis of the Women’s Health Initiative, continuous combined use of estrogen plus progestin reduces the risk of endometrial cancer among postmenopausal women. The study was reported at the 2013 European Cancer Congress by Rowan T. Chlebowski, MD, PhD, Professor and Chief of...
Expert Point of View: Kjell Oberg, MD, PhD
Kjell Oberg, MD, PhD, Professor in the Department of Medical Sciences at the University Hospital in Uppsala, Sweden, discussed the CLARINET paper at the Presidential Session during the European Cancer Congress in Amsterdam. Dr. Oberg noted the curious observation that median progression-free...
Extended-Release Lanreotide Significantly Delays Disease Progression in Patients With Neuroendocrine Tumors in Large Phase III CLARINET Trial
A strong antiproliferative response was shown for the somatostatin analog lanreotide (subcutaneous, extended-release formulation, Somatuline Autogel [Somatuline Depot in the United States]) in patients with gastroenteropancreatic neuroendocrine tumors, in the large multinational prospective phase...
Expert Point of View: Sibylle Loibl, MD
Sibylle Loibl, MD, of the German Breast Group and the Klinikum Offenbach in Germany, discussed the NeoALTTO findings at the European Cancer Congress, noting that this trial is one of several studies that all point to one conclusion: Pathologic complete response rates are lower in HER2-positive...
PIK3CA-Mutant Tumors Not Likely to Respond to Neoadjuvant HER2 Blockade
In early breast cancer patients receiving anti-HER2 therapy in the NeoALTTO trial, mutations in PIK3CA were associated with lower rates of pathologic complete response, according to a study reported at the 2013 European Cancer Congress by José Baselga, MD, Physician-in-Chief at Memorial...
Expert Point of View: Elzbieta Senkus-Konefka, MD, PhD
Elzbieta Senkus-Konefka, MD, PhD, of the Medical University of Gdansk, Poland, the formal discussant of the paper at the European Cancer Congress, took exception with the authors’ conclusion that radiotherapy may not be effective in all subtypes. “I don’t agree that luminal B and HER2-enriched...
Radiotherapy Benefit in Young Women With Node-Positive Breast Cancer May Vary by Intrinsic Subtypes
Radiation therapy appears to significantly decrease local recurrence in premenopausal women with node-positive and luminal A tumors, based on an analysis of two small but independent randomized series reported at the 2013 European Cancer Congress in Amsterdam.1 “Though not definitive, our study...
Sharing Treatment Decision-Making With Patients: Where’s the Evidence of Value?
Though certainly not new to oncologists, “shared decision-making” between doctors and patients is receiving increased attention in the medical community today. While it’s an idea with merit, Steven J. Katz, MD, MPH, a specialist in quality care issues, maintains that expectations about the...
Meta-Analysis Upholds Benefit in Progression-Free Survival, but Not Overall Survival, With Lenalidomide Maintenance
Multiple myeloma patients derived a benefit from maintenance lenalidomide (Revlimid) treatment in terms of progression-free but not overall survival, according to a meta-analysis of four key trials presented at the 2013 American Society of Hematology (ASH) Annual Meeting.1 The study does little to...
IFM 2005-02 Update Differs From CALGB 100104: Why?
The updated analysis of the Intergroupe Francophone du Myelome (IFM) 2005-02 trial in newly diagnosed multiple myeloma patients showed that lenalidomide (Revlimid) maintenance prolongs progression-free survival after stem cell transplantation, but does not improve overall survival, according to...
Surprising Findings for Lenalidomide Maintenance in Updated IFM 2005-02 Analysis
A new analysis of the multiple myeloma Intergroupe Francophone du Myelome (IFM) 2005-02 trial showed that lenalidomide (Revlimid) maintenance prolongs progression-free survival after stem cell transplantation, but does not improve overall survival.1 This is possibly attributed to the shorter...
Expert Point of View: Debu Tripathy, MD
Debu Tripathy, MD, Professor of Medicine, Co-Leader of the Women’s Cancer Program, and the Priscilla and Art Ulene Chair in Women’s Cancer at the University of Southern California Norris Cancer Center, Los Angeles, commented on the APT study for The ASCO Post. “In treating early-stage...
HER2-Positive Breast Cancer Patients With Small Tumors Benefit From Low-Toxicity Regimen
There may be a benefit for treating small HER2-positive tumors—a breast cancer subset for whom treatment recommendations have not been established but for whom there is still risk of recurrence—and this can be done with little toxicity, according to a multicenter study presented at the 2013 San...
Seven Studies at SABCS Make Dr. Jame Abraham's List of 'Practice-Changing' Talks
From December 10 to 14, the American Association for Cancer Research, the Cancer Therapy & Research Center at The University of Texas Health Sciences Center at San Antonio, and Baylor College of Medicine once again hosted the San Antonio Breast Cancer Symposium (SABCS), presenting...
Who Opts for Chemoprevention?
Based on age and risk, an estimated 10 million women in the United States may be eligible for an agent aimed at preventing breast cancer, but chemoprevention is underutilized. Fewer than 5% of women at high risk who are offered tamoxifen for chemoprevention agree to take the drug, partly due to...
Expert Point of View: Matthew Ellis, MB, PhD
Matthew Ellis, MB, PhD, Professor of Medicine and the Anheuser-Busch Chair in Medical Oncology at Washington University School of Medicine, St. Louis, commented for The ASCO Post on the emerging field of research on drugging PI3K mutations. Critical Mechanisms “Multiple somatic lesions in breast...
Drugging PI3K in Breast Cancer: Findings From SABCS 2013
Components of the phosphatidylinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway are deregulated in many human cancers, with about 30% of breast cancers harboring PIK3CA gene mutations. Emerging research shows that these mutations may render estrogen receptor alpha-positive tumors ...
Common Mutations May Impact Neoadjuvant Treatment Outcomes in Breast Cancer
Emerging research is suggesting that outcomes from neoadjuvant chemotherapy may be correlated with two genetic mutations that are common in breast cancer—PIK3CA and TP53. Their presence may affect response to treatment, and mutational shift after treatment may affect survival, according to studies...
Expert Point of View: Andrew D. Zelenetz, MD, PhD
Andrew D. Zelenetz, MD, PhD, Chair of the Non-Hodgkin Lymphoma Guideline Panel of the National Comprehensive Cancer Network (NCCN) and former Chief of the Lymphoma Service at Memorial Sloan-Kettering Cancer Center, New York, commented on the study by Yamshon et al for The ASCO Post. He said the...
‘R-Squared’ Lymphoma Treatment: Possible Markers of Response Identified
A correlative analysis of a study evaluating lenalidomide (Revlimid) plus rituximab (Rituxan) in patients with indolent non-Hodgkin lymphoma found that increases in the levels of several cytokines correlated with response to treatment. The study by investigators from the University of California...
Expert Point of View: Nathan Fowler, MD
“The future is increasingly bright for patients as we move into an era of effective nonchemotherapy treatment options,” commented Nathan Fowler, MD, Associate Professor in the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center, Houston. “Over the past several years, ...
Lenalidomide/Rituximab Doublet a Potential Front-Line Treatment in Some Lymphomas
The biologic doublet of lenalidomide (Revlimid) plus rituximab (Rituxan) can achieve high response rates and durable remissions in lymphoma, according to a parade of phase II studies presented at the 2013 American Society of Hematology (ASH) Annual Meeting in New Orleans. The immunomodulatory agent ...
Expert Point of View: Lajos Pusztai, MD, DPhil
Lajos Pusztai, MD, DPhil, Professor of Medicine and Director of Breast Medical Oncology at Yale University, New Haven, Connecticut, who was the formal discussant of the papers by Sikov et al and Rugo et al, said there is mounting evidence for using carboplatin. He and his own research team have...
Addition of Carboplatin to Standard Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Supported by SABCS Studies
The achievement of a pathologic complete response in patients with triple-negative breast cancer was boosted by the addition of carboplatin to a standard neoadjuvant chemotherapy regimen, and by the addition of veliparib, an investigational oral PARP inhibitor, plus carboplatin to a standard...
Expert Point of View: Bruce Cheson, MD
Ibrutininb appears to be the most promising drug we have seen in Waldenstrom’s macroglobulinemia and will likely significantly change the therapeutic landscape,” according to Bruce Cheson, MD, Deputy Chief, Hematology-Oncology and Head of Hematology Research at Georgetown Lombardi Cancer Center in...
Ibrutinib Induces Prompt and Durable Responses in Some Lymphomas
The Bruton’s tyrosine kinase inhibitor ibrutinib (Imbruvica) is changing the landscape of treatment in chronic lymphocytic leukemia. New research with the drug in lymphoma, presented at the 2013 American Society of Hematology (ASH) Annual Meeting in New Orleans, indicates it may be of benefit in...
Expert Point of View: Andrew D. Zelenetz, MD, PhD
Andrew D. Zelenetz, MD, PhD, Chair of the Non-Hodgkin Lymphoma Guideline Panel of the National Comprehensive Cancer Network (NCCN) and former Chief of the Lymphoma Service at Memorial Sloan-Kettering Cancer Center, New York, put the latest maintenance trials into perspective for The ASCO Post....
ASH Studies Confirm Benefit of Rituximab Maintenance in Follicular Lymphoma
Findings from two major studies presented at the 2013 American Society of Hematology Annual Meeting not only confirm the benefit of rituximab (Rituxan) maintenance in follicular lymphoma, but also indicate that the longer the maintenance period, the greater the impact on progression-free survival....
Novel Agents Show Activity in Non-Hodgkin Lymphoma
PI3K-mediated activation of downstream effectors allows tumors to escape from negative growth control, and this action may be checked with PI3K inhibitors. At the 2013 American Society of Hematology (ASH) Annual Meeting, researchers reported results in patients with relapsed or refractory lymphoma...
ASH Studies Refine Myeloma Treatment and Show Promise for New Agents
Multiple myeloma researchers moved the field forward at the 2013 American Society of Hematology (ASH) Annual Meeting, presenting evaluations of treatment schedules and reports of encouraging activity with compounds in development. Alternating vs Sequential Regimens In 231 newly diagnosed elderly...
Postmastectomy Pain Effectively Treated With a Simple Injection
For postmastectomy neuropathic pain, perineural infiltration with a combination of bupivacaine and dexamethasone is a “simple, effective, practice-changing treatment that any surgeon can do,” according to Laura J. Esserman, MD, MBA, Professor of Surgery and Radiology at the University of...
SABCS Highlights Include Findings in Triple-Negative Disease, Protective Effects of Exercise, and the Adherence-Copay Link
The San Antonio Breast Cancer Symposium brings together specialists from all over the world who focus on management of breast cancer. We have covered many of the important presentations in the pages of The ASCO Post and in our online Evening News. Below are summaries of additional noteworthy...
Expert Point of View: Neal J. Meropol, MD
Neal J. Meropol, MD, Chief of Hematology and Oncology at University Hospitals Seidman Cancer Center and Case Western Reserve University, discussed the CAIRO3 results at the Gastrointestinal Cancers Symposium. He said there are three main lessons from CAIRO3: (1) It is feasible yet challenging to...
Maintenance Treatment With Capecitabine and Bevacizumab Is Effective in Metastatic Colorectal Cancer
In patients with metastatic colorectal cancer, maintenance treatment with capecitabine plus bevacizumab (Avastin) after induction treatment with capecitabine, oxaliplatin, and bevacizumab (CAPOX-B) significantly delayed disease progression, compared to observation, according to the final results of ...
Expert Point of View: Manish Shah, MD
Manish Shah, MD, Director of Gastrointestinal Oncology and Associate Professor of Medicine at New York–Presbyterian/Weill Cornell Medical Center in New York, discussed the findings of the RAINBOW trial at the 2014 Gastrointestinal Cancers Symposium. Dr. Shah noted that in this “well sized” study,...
Ramucirumab Plus Paclitaxel Improves Overall Survival After First Progression in Metastatic Gastric Cancer
In the global phase III RAINBOW trial in patients with metastatic gastric cancer, the investigational monoclonal antibody ramucirumab significantly improved both progression-free and overall survival, when added to paclitaxel in second-line therapy, as reported at the 2014 Gastrointestinal Cancers...
Expert Point of View: Rebecca Miksad, MD, MPH
Rebecca Miksad, MD, MPH, Assistant Professor of Medicine at Harvard Medical School and Attending Physician, Gastrointestinal Medical Oncology, Beth Israel Deaconess Medical Center, Boston, discussed the findings at the symposium and the potential for immunotherapy in pancreatic cancer....
Immunotherapy Duo Improves Survival in Metastatic Pancreatic Cancer
Overall survival was improved in metastatic pancreatic cancer patients through an innovative immunotherapy strategy in a multicenter study reported at the 2014 Gastrointestinal Cancers Symposium.1 “This is the first time a randomized study has shown that immunotherapy is effective in pancreatic...
